Skip to main content

Table 2 KRAS mutations

From: Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease

Exon

Codon

Hot spot site

Amino acid

No. of patients

%

2

12

  

24

40.6

  

c.34 G>A

p.Gly12Ser

1

1.6

  

c.35 G>A

p.Gly12Asp

15

25.4

  

c.35 G>T

p.Gly12Val

7

11.8

  

c.35 G>C

p.Gly12Ala

1

1.6

 

13

  

4

6.7

  

c.37_39 dupl

p.Gly13 dupl

1

1.6

  

c.37

-

-

-

  

c.38 G>A

p.Gly13Asp

3

5